中国汉族急性白血病患儿化疗药物不良反应与CYP3A5^＊3的关联性研究  

The Relationship between CYP3A5＊3 Polymorphism and Drug Adverse Reaction of Pediatric Acute Leukemia

作　　者：刘艳[1] 盛琦[2] 林志燕[1] 王芳[1] 田怀平[1] 徐阿晶[1] 张健[1] 

机构地区：[1]上海交通大学医学院附属新华医院药剂科,上海200092 [2]上海交通大学医学院附属新华医院儿童血液科,上海200092

出　　处：《现代生物医学进展》2013年第8期1486-1488,1458,共4页Progress in Modern Biomedicine

基　　金：国家自然科学基金青年基金项目(81202598);上海市卫生局课题(2009068);上海市科委(11DZ1972500;12DZ1930404)

摘　　要：目的:探讨中国汉族儿童CYP3A5*3与白血病药物不良反应的关联。方法:入选2004年7月至2011年6月间确诊的急性白血病儿童52名,用PCR-RFLP方法测定CYP3A5*3突变,同时收集病人常规资料和不良反应。结果:白血病儿童主要不良反应为呕吐、口腔黏膜损害、一过性骨髓抑制、肝功能损害。且CYP3A5*3/*3病人相对于其他两组,更易于发生白细胞减少和粘膜损害。结论:CYP3A5*3与病人的不良反应发生密切相关,可作为白血病治疗效果预测基因。Objective： To investigate the relationship between CYP3A5＊3 and drug adverse reaction of pediatric acute leukemia. Method： 52 acute lymphoblastic leukemia patients were enrolled in this study. PCR-RFLP was used to identify CYP3A5＊3 polymorphism, and then collected the data of drug adverse reaction. Results： Main adverse reactions include vomiting, mucosal damage, hematologic damage, and hepatic function damage. The CYP3A5＊3 was a high risk factor for leukopenia and mucosal damage. Conclusion： The CYP3A5＊3 variant could change gene＇s function, and then has an impact on the drug elimination, then lead to higher toxicity in clinical. This variant may be used as a predictive marker for higher risk of drug adverse reaction.

关 键 词：药物代谢酶 儿童白血病 基因变异 CYP3A5＊3 

分 类 号：R968[医药卫生—药理学]